» Articles » PMID: 28551685

Concordance of HER2 Immunohistochemistry and Fluorescence Hybridization Using Tissue Microarray in Breast Cancer

Overview
Journal Anticancer Res
Specialty Oncology
Date 2017 May 29
PMID 28551685
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

Aim: Immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) are common methods for assessment of human epidermal growth factor receptor 2 (HER2) in breast cancer.

Materials And Methods: In a cohort of 498 consecutive patients with breast cancer, we examined concordance between IHC and FISH for HER2 on tissue microarray (TMA) sections. In a subset of 116 specimens, we examined HER2 concordance from the block used for diagnostics and a randomly-chosen additional block (a proxy of the core biopsy).

Results: Overall concordance between both methods on TMA sections was 93.8% and between HER2, determined on diagnostic and additional blocks, was 93.6% for IHC and 98.0% for FISH.

Conclusion: Since some cases were discordant, we suggest that both methods be used for HER2 assessment. The lower concordance rate between diagnostic and additional blocks using IHC compared to FISH suggests a greater variability of IHC staining across tumor regions than for FISH results.

Citing Articles

Low and Ultra-Low HER2 in Human Breast Cancer: An Effort to Define New Neoplastic Subtypes.

Franchina M, Pizzimenti C, Fiorentino V, Martini M, Ricciardi G, Silvestris N Int J Mol Sci. 2023; 24(16).

PMID: 37628975 PMC: 10454084. DOI: 10.3390/ijms241612795.


The Evolution of Targeted Radionuclide Diagnosis of HER2-Positive Breast Cancer.

Bragina O, Deyev S, Chernov V, Tolmachev V Acta Naturae. 2022; 14(2):4-15.

PMID: 35923562 PMC: 9307982. DOI: 10.32607/actanaturae.11611.


Circulating tumor cell assay to non-invasively evaluate PD-L1 and other therapeutic targets in multiple cancers.

Page R, Patil D, Akolkar D, Murthy S, Bendale K, Patil R PLoS One. 2022; 17(6):e0270139.

PMID: 35714131 PMC: 9205490. DOI: 10.1371/journal.pone.0270139.


Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines.

Burguin A, Furrer D, Ouellette G, Jacob S, Diorio C, Durocher F PLoS One. 2020; 15(6):e0234991.

PMID: 32584853 PMC: 7316326. DOI: 10.1371/journal.pone.0234991.


A review on methods for diagnosis of breast cancer cells and tissues.

He Z, Chen Z, Tan M, Elingarami S, Liu Y, Li T Cell Prolif. 2020; 53(7):e12822.

PMID: 32530560 PMC: 7377933. DOI: 10.1111/cpr.12822.